Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price traded up 71.4% on Wednesday . The stock traded as high as C$0.12 and last traded at C$0.12. 592,088 shares traded hands during trading, an increase of 516% from the average session volume of 96,162 shares. The stock had previously closed at C$0.07.
Hemostemix Stock Up 71.4 %
The stock has a market cap of C$10.45 million, a price-to-earnings ratio of -6.00 and a beta of 0.20. The stock’s fifty day moving average is C$0.08 and its 200-day moving average is C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- What is an Earnings Surprise?
- Work and Play: Investing in the Rise of Bleisure Travel
- Top Stocks Investing in 5G Technology
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- What is a Low P/E Ratio and What Does it Tell Investors?
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
